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Wim J.M. Smit, Marianne A. Nooij, Emile Voest, Pierre Hupperets, Els M. TenVergert, Harm van Tinteren,
Pax H.B. Willemse, Marian J.E. Mourits, Neil K. Aaronson, Wendy J. Post, and Elisabeth G.E. de Vries
A B S T R A C T
Purpose
To evaluate and compare health-related quality of life (HRQOL) after conventional- and high-dose
adjuvant chemotherapy in patients with high-risk breast cancer.
Patients and Methods
Patients were randomly assigned to either a conventional or high-dose chemotherapy regimen;
both regimens were followed by radiotherapy and tamoxifen. HRQOL was evaluated until disease
progression using the Short Form-36 (SF-36), Visual Analog Scale, and Rotterdam Symptom
Checklist and assessed every 6 months for 5 years after random assignment. For the SF-36, data
from healthy Dutch women with the same age distribution served as reference values.
Results
Eight hundred four patients (conventional-dose chemotherapy, n  405; high-dose chemotherapy,
n  399) were included. Median follow-up time was 57 months. Directly after high-dose
chemotherapy, HRQOL decreased more compared with conventional chemotherapy for all SF-36
subscales. After 1 year, the reference value of healthy women was reached in both groups. Small
differences were observed between the two groups in the role-physical and role-emotional
subscales, but 1 year after treatment, these differences were minor and not clinically relevant.
During follow-up, patients with a lower educational level and many complaints before chemother-
apy experienced a worse HRQOL.
Conclusion
Shortly after high-dose chemotherapy, HRQOL was more affected than after conventional-
dose chemotherapy. One year after random assignment, differences were negligible. Identi-
fying patients who have a higher chance of persistent impaired quality of life after treatment
(which, in the present study, included patients with a lower educational level and many
complaints before chemotherapy) is important and may open the way for better patient-
tailored prevention strategies.
J Clin Oncol 25:5403-5409. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Adjuvant therapy is administered increasingly to
women with breast cancer, resulting in delayed dis-
ease recurrence and improved survival. Because of
the dismal prognosis of patients with extensive axil-
lary nodal involvement, over the last 10 years, a
variety of new treatment regimens has been tested.
These include adjuvant dose-dense as well as high-
dose chemotherapy with hematopoietic stem-cell
reinfusion. A number of randomized studies have
been performed.1 A recent meta-analysis shows a
significantbenefit inevent-free survival for thehigh-
dose group at 3 and 4 years. Overall survival rates
were not significantly different, butmost studies are
still immature.1
Relatively little is known about the long-term
effects of adjuvant therapy on patients’ well-being.
Long-termdata concerninghealth-relatedquality of
life (HRQOL) in breast cancer patients after chem-
otherapy, particularly after high-dose chemothera-
py, are limited.2-10Most studies used cross-sectional
designs with small and heterogeneous patient sam-
ples and relatively short follow-up.
In a Dutch randomized, multicenter study,
high-dose chemotherapy improved relapse-free
survival of stage II and III breast cancer patients
with 10 ormore positive axillary lymph nodes.11 An
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update showed a trend for a better relapse-free survival in the high-
dose arm. For the 621 patients withHER2/neu-negative disease there
was a relapse-free survival and survival benefit with high-dose thera-
py.12HRQOLwas includedasa secondaryendpoint. In this article,we
report the longitudinal HRQOL results of this trial.
PATIENTS AND METHODS
Patients
Patients with stage II or III breast cancer were eligible for the trial if they
had four positive axillary lymph nodes, had an EasternCooperativeOncol-
ogy Group-Zubrod performance status of 0 or 1, and were younger than 56
years. Before random assignment, patients were stratified according to age
( 50 v 50 years), menopausal status (premenopausal v postmenopausal),
numberof lymphnodemetastases (four toninev10metastases), and tumor
size (pT1 v pT2 v pT3).11,12
Treatment Regimens
Patients received either five cycles of fluorouracil (500mg/m2), epirubi-
cin (90 mg/m2), and cyclophosphamide (500 mg/m2) or four cycles of the
same chemotherapy followed by one cycle of high-dose chemotherapy con-
sisting of cyclophosphamide (6 g/m2), thiotepa 480 (mg/m2), and carboplatin
(1,600 mg/m2) over 4 days and autologous peripheral stem-cell reinfusion.
The original protocol included tamoxifen 40 mg daily for 2 years. During the
trial, it became clear that 5 years of tamoxifen were superior to 2 years.
Therefore, patients with hormone receptor–positive cancer continued to re-
ceive tamoxifen for a total of 5 years.11 The medical ethical committee of
the participating hospitals approved the study, and all patients gave in-
formed consent.
HRQOL
HRQOL was assessed by means of a Visual Analog Scale (VAS) for
general health perception, the Short Form-36 Health Survey (SF-36), and the
Rotterdam Symptom Checklist (RSCL). The VAS scale ranged from 0 (worst
imaginable health state) to 100 (best imaginable health state).
The SF-36 is organized into eight scales assessing physical functioning,
role-physical, bodilypain, generalhealth,mentalhealth, role-emotional, social
functioning, and vitality.13 Scale scores range from0 to 100,with higher scores
representing a higher level of functioning. Reference data for healthy Dutch
women (mean age, 47 years; range, 16 to 96 years) were available for compar-
ison.14Theoutcomeof the SF-36 is agedependent.The agedistribution in this
study is skewed (range, 24 to 56 years). Therefore, six age categories were
identified. Within each age category, one reference healthy woman could be
sampled for every four breast cancer patients. This way, 199 reference women
were identified, and their data on the eight scales of the SF-36 were used. The
calculatedmean values were used as references values.
TheRSCL is a cancer-specific tool tomeasurepsychological andphysical
distress in cancer patients. Patients indicated the degree to which they have
been bothered by the 30 indicated symptoms in the past week.15 The distribu-
tion of theRSCL item scoreswas highly skewed. Therefore, the 4-point Likert-
type response scales were collapsed into the presence/absence of each
symptom. Sociodemographic characteristics including age, education,marital
status, number of children living at home, and employment status were col-
lected at baseline.
Follow-Up
Patients received the questionnaires bymail before random assignment,
after chemotherapy completion, after radiotherapy completion, and every 6
months thereafter. The data reported cover a maximum of 5 years after
random assignment (maximum of 12 assessments).
Statistical Analysis
Theplanned sample sizewas basedon the primary endpoints of disease-
free and overall survival. The HRQOL data were analyzed according to the
intent-to-treat principle. Data of patients who had not yet reached the 5-year
follow-up were included in the analysis until their last follow-up. Question-
naires of patients who experienced relapse or diedwithin 5 years after random
assignment were included in the analyses until disease relapse or death. Statis-
tical analysis was performed using SPSS version 11.0 (SPSS Inc, Chicago, IL)
and Multi Level-wiN version 1.10 (Bristol Institute of Public Affairs, Bristol,
United Kingdom).16
Student’s t test for independent samples and the 2 test were used to
compare sociodemographic and baseline HRQOL scores of the two arms. At
the 1-year follow-up, the t test was used to compare mean SF-36 scores of the
two arms with those of the age-matched reference group from the general
Dutch population.
Mixed-effects analysis of variance models for repeated measures was
used to assess longitudinal HRQOL changes within and between treatment
arms.17 At random assignment, there was no difference in HRQOL between
the two groups. This information was put into themixed-effects analysis. Age
( 50 v  50 years) and menopausal status were separately included as
covariates. P .05 was considered statistically significant.
Effect size is defined as the mean HRQOL score difference between the
high-dose and conventional-dose groups divided by the standard deviation of
theHRQOLscores of the total groupat thatmeasurementmoment.Avalueof
0.2 to 0.5 is considered indicative of a small effect, 0.5 indicates a medium
effect, and 0.8 indicates a large effect size.18
RESULTS
Patients
FromAugust 1993 to July 1999, 885 patients were enrolled onto
the clinical trial.11,12 The HRQOL component of the trial began after
47 patients had been entered. Of the remaining 838 patients, 34 (4%)
didnot participate (27patients declined, and sevendidnot participate
as a resultof logistical reasons).Of the804patientswhoparticipated in
the HRQOL study, 405 received conventional-dose chemotherapy,
and 399 received high-dose chemotherapy. Forty-one patients ran-
domly assigned to high-dose therapy did not receive this treatment.11
According to the intent-to-treat principle, they were included in the
high-dose arm for analysis.Noneof the patients randomly assigned to
conventional-dose chemotherapy received high-dose chemotherapy.
Compliance With HRQOL Questionnaires
HRQOL data collected up to 5 years after random assignment
were included in the analysis. The median follow-up time was 57
months. Figure 1 shows response rates for theHRQOLquestionnaires
at baseline and during follow-up. The overall response rate was 86%
(range, 73% to 95%) at the various assessment points. No significant
differences in compliancewere observed between the treatment arms.
Two hundred four patients (25%; 100 in conventional-dose group
and104 inhigh-dose group)hadnot yet reached the5-year follow-up.
At the time of analysis, 325 patients (40%; 156 in conventional-dose
group and 169 in high-dose group) were disease free at 5 years of
follow-up.
Sociodemographic Characteristics
Patient characteristics at random assignment were well balanced
between the treatment arms (Table 1).At randomassignment, 50%of
the patients (n  400) were employed, and 80% (n  646) had
children.Therewerenosignificantdifferencesbetween thearms in the
percentage of patients employed at random assignment or at 1 or 3
years after random assignment or in the number of hours per week
worked. At follow-up, 34% of all patients reported working less ( 4
hours per week) than at trial entry, 48% indicated that this had not
changed, and 18%workedmore.
Buijs et al
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HRQOL Outcomes
VAS. The results of the mixed-effects model analysis for
VAS scores and effect sizes over time for both arms are illustrated in
Figure 2. At baseline, there was no statistically significant difference
in VAS scores between the treatment arms. Until 24 months, the
conventional-dose group scored statistically significantly higher than
the high-dose group. Just after chemotherapy, there was a large effect
size (0.82), and until 24 months, a small effect size (0.18 to 0.36) was
seen. Thereafter, no significant between-group differences in VAS
score were observed over time.
SF-36. The results of the mixed-effects models for all sub-
scales of the SF-36 during follow-up in both arms are presented in
Figure 3, as well as the normal reference values and the effect sizes. At
baseline, there were no significant differences between the arms in
SF-36 scores. Both patient groups scored lower on two SF-36 sub-
scales, role-physical and role-emotional, than the general population
reference sample.
Directly after chemotherapy, the high-dose group scored statisti-
cally significantly lower for all subscales, with effect sizes all greater
than 0.5. Only the scores on general health did not differ between the
two arms. For the subscales of mental health, role-emotional, social
functioning, and bodily pain, no significant differences between the
two armswere seen 6months after randomassignment and later, and
effect sizes were always less than 0.20. At 2.5 years after random
assignment, the high-dose group had lower scores for role-physical
compared with the conventional-dose group, but the effect sizes dur-
ing this period were less than 0.2.
For the subscales of physical functioning and vitality, a small but
significant differencewas observedbetween the two armsduring the 5
years of follow-up. The effect sizes during those yearswere just greater
than 0.20 for physical functioning and just less than 0.20 for vitality.
For all subscales, except for role-physical in both arms and phys-
ical functioning for the high-dose group, scores returned tonormal or
greater than reference values at 1 year. Thereafter, all HRQOL scores
remained stable over the next 4 years.
Correlation between age,menopausal status in the SF-36, andVAS
scores. The covariates of age and menopausal status had significant
effects on the subscales of physical functioning and role-physical. In
both arms, physical functioning scores of youngerwomen (50years
at randomassignment)were significantly higher comparedwitholder
women at all time points. From1 to 5 years after randomassignment,
differences between younger and older women were statistically sig-
nificant, but effect sizes were small. Patients who were postmeno-
pausal at random assignment scored significantly lower on the role-
physical subscale compared with patients who were premenopausal
over the whole 5-year period.
RSCL. Tiredness, decreased sexual interest, sweating, and pain-
ful muscles were the most prevalent symptoms. The percentage of
Conventional dose completed
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Fig 1. Number of patients in the conventional-dose and high-dose treatment
groups who returned the health-related quality of life questionnaire during
treatment and follow-up.
Table 1. Characteristics of the Patients at Random Assignment
Characteristic
No. of Patients


















Grammar school 16 17
High school 281 273
Entered some college 76 60
Completed college 17 34
Unknown 15 14
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Fig 2. Mean scores of the Visual Analog Scale (VAS) in the high-dose group (Œ)
and conventional-dose group (f) at random assignment and during 5 years of
follow-up and effect size (). The x axis shows time in months. Left y axis
represents VAS score, and right y axis represents the effect size. Significant
difference between the high-dose and conventional-dose groups is indicated
with an asterisk (*).
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patients reporting tiredness and decreased sexual interest over time is
shown in Figure 4. Just after chemotherapy, the percentage of patients
with physical symptoms was higher compared with baseline in both
arms.Overall, thepercentageof patientswith symptomswashigher in
the high-dose group. This difference was already largely reduced 6
months after random assignment. During the follow-up period, 10%
of the patients (n 78) experienced three or four of the most preva-
lent symptoms formore thanhalf of the time.Comparedwithpatients
without this high frequency of complaints, these patients could only
bedistinguishedbya lower education level.The seven items indicating
psychological distress (irritability, worrying, depressed mood, ner-
vousness, despairing about the future, tension, and anxiety) dimin-
ished in both arms from random assignment up to 1 year later and
remained constant over the next 4 years. After 5 years, 244 patients
completedHRQOL questionnaires, and 33%of the patients reported
no symptoms, 17% experienced one symptom, 13% experienced two
symptoms, 9% experienced three symptoms, and 28% experienced
four or more symptoms of the RSCL.
Decreased sexual interest was the most prevalent symptom
(36%). Patients with many symptoms ( four) and few symptoms
( three) showed no differences with regard to treatment arm, age,
employment status, numberofworkinghours at randomassignment,
having children and children living at home, marital status, meno-
pausal status at random assignment, or education level. Patients with
many symptoms after 5 years scored significantly lower on all SF-36
subscales at random assignment and at the 11 measurement points
thereafter comparedwith other patients. The only exceptionwas role-
physical at random assignment. In Figure 5, the scores over time for
the subscale of bodily pain for the patients with many and few com-
plaints are shown.The results forother subscalesof SF-36andVASare
comparable andnot shown. Eighty percent of patients having three
symptoms of the RSCL at randomassignment reported three com-
plaints after 5 years, and half of all patients scoring four symptoms
at random assignment scored four symptoms after 5 years.
DISCUSSION
This prospective, longitudinal study describes HRQOL for 5 years
afterrandomassignmentbetweenconventional-andhigh-dosechem-
otherapy in a large group of disease-free, high-risk breast cancer pa-
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Fig 3. Mean Short Form-36 Health Survey (SF-36) subscales scores in the high-dose group (Œ) and conventional-dose group (f) and reference values from
age-corrected controls (– – – –) and effect size () at random assignment and during 5 years of follow-up. The x axis shows time in months. Left y axis represents SF-35
score, and right y axis represents effect size. Significant difference between the high-dose and conventional-dose groups is indicated with an asterisk (*).
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slightly different from an age- and sex-matched control group ob-
tained from the general Dutch population. During the immediate
post-treatment period, HRQOL was worse in the high-dose than in
the conventional-dose treatment group. However, 1 year after ran-
dom assignment, HRQOL in both groups was again comparable to
the general population reference values, and these levels remained
relatively constant over the next 4 years.
Comparison ofHRQOL studies is relevant but can be hampered
by differences in study designs and measures used.19 In the future,
disease-specific questionnaires, such as the Functional Assessment of
Cancer Therapy–Breast,might be able to detect additional differences
that the SF-36, for example, does not reveal.
A small cross-sectional study in 43 patients with 2 years of me-
dian follow-up after high-dose chemotherapy reported higher
HRQOL scores compared with patients receiving conventional-dose
chemotherapy using the Functional Living Index Cancer question-
naire.However, the scoreson this questionnairedifferedonlymargin-
ally between the two groups.20 Another study, which compared pre-
and post-treatmentHRQOL, observed that disease-free breast cancer
patients (n 24) after high-dose chemotherapy had higher HRQOL
than before treatment.3 The investigators excluded all patients who
experienced relapse or died during follow-up from the analysis. To
achieve an objective rating of HRQOL, data of all patients were in-
cluded in our study until disease relapse or death.
Although research on HRQOL in breast cancer patients has be-
come increasingly sophisticated, few longitudinal studies have as-
sessed patients before and after treatment.7,9,10,21 Longitudinal
HRQOLstudies layaconsiderable claimto thecomplianceofpatients,
requiring frequent HRQOL questionnaires to be returned.6 Objec-
tively and compared with others, our overall response rate was high
(86%).7,9,10 Most longitudinal HRQOL studies are analyzed with
repeated-measurement analysis of variance, and one missing ques-
tionnaire will result in omitting all data of that particular patient.
Analysis by mixed-effects models, as performed in our study, has the
advantages that all data can be used and selection bias is excluded.
One large, randomized, prospective study with serial assessment
points compared HRQOL of patients receiving adjuvant high-dose
chemotherapy (n 197) or tailored chemotherapy (n 211). This
study showed a larger decrease in HRQOL and faster recovery in the
high-dose group compared with the tailored group during the first
year.7 Similar to our findings, HRQOL had returned to baseline in
both groups 1 year after treatment. The fasterHRQOL recovery in the
high-dose group can be explained by the fact that the tailored arm
actually had received more chemotherapy over a longer period of
time.7 Another prospective study comparedHRQOLof breast cancer
patients until 3 years after high-dose chemotherapy (n  106) or
intermediate-dose chemotherapy (n  104). HRQOL was compro-
mised transiently among patients in the high-dose group but not
among patients in the intermediate-dose group.10 One explanation
for this finding could be the fact that the first assessment took place 3
months after chemotherapy, therebymissing the transient decrease in
HRQOL in the intermediate-dose group. Availability ofHRQOLdata
of healthywomen allowedus to interpretHRQOL in amore balanced
manner.TheHRQOLofourpatients seemed tobecomparable to that
of healthy women of the same age.With frequent assessments, others
found a decrease in HRQOL in both arms, similar to our observa-
tions.7 In another prospective longitudinal breast cancer study in 52
patients after high-dose chemotherapy, HRQOL was measured re-
peatedly from baseline over 2 years. HRQOL decreased but had re-
turned to baseline 8 weeks after treatment.9 Although our study and
the previously mentioned studies differ in many aspects, 1 year after
treatment, nodifferences inHRQOLbetween the treatment groupsor
from baseline were found by all four studies.7,9,10
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Fig 4. Percentage of patients reporting symptoms by the Rotterdam Symptom
Checklist (3  quite a bit, 4  very much) at each assessment point for patients
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Fig 5. Mean scores of the Short Form-36 Health Survey subscale of bodily pain
for patients with many ( four symptoms []) and few symptoms ( three
symptoms; [f]) and reference values from age-corrected controls (– – – –) at
random assignment and during 5 years of follow-up. The x axis shows time in
months. The y axis represents bodily pain score.
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In our study, patients generally reported a few (late) symp-
toms, but some complaints persisted for several years. Remarkably,
single symptoms apparently did not have a severe influence on
HRQOL. Decreased sexual interest was the most prevalent symp-
tom. Impaired sexual functioning represents a well-known specific
long-term sequela of breast cancer patients.4,9,22,23 In part, this can
be a result of premature ovarian failure caused by chemotherapy.9
Tiredness, painful muscles, and sweating were also frequently re-
ported. Interpreting these results is difficult because healthy post-
menopausal women also commonlymention these symptoms.We
have earlier shown that (lower) mental health was the strongest
predictor for tiredness in a subpopulation of the current study.24
Patients with repeated multiple complaints were, in the current
analysis, characterized by a lower educational level. A few other
studies have also observed this relationship. Kornblith et al25 no-
ticed that breast cancer survivors with a lower education level had
more problems adapting to post-traumatic stress 20 years after
adjuvant therapy. In a study of 2,208 women with breast cancer or
at risk for breast cancer, womenwith a lower educational level were
more likely to be bothered by symptoms.26 In our study, the 10%of
patients with repeated multiple complaints are characterized by a
lower education level. In addition, for 5-year disease-free survi-
vors, we analyzed whether complaints mentioned in the RSCL at
random assignment predicted their HRQOL at 5 years. This anal-
ysis revealed that half of patients with four or more symptoms at 5
years also had many complaints at random assignment. This indi-
cates that having complaints before chemotherapy predicts a worse
HRQOL outcome.
The HRQOL of breast cancer patients in our study, 1 to 5 years
after treatment, is comparable to healthy women. Only small, clini-
cally irrelevant differences were observed between the treatment
groups. Therefore, the impact of both chemotherapy regimens on
HRQOL is clearly less severe than expected. HRQOL recovers swiftly
after adjuvant treatment. Women with poor prognosis breast cancer,
who are engaged in intensive treatment protocols, tend to adapt to
their new situation and to modify their reference points. The emo-
tional and social support of relatives, friends, and medical staff can
contribute to their adaptation.27 Identifying patients who have a
higher chanceofpersistent impairedqualityof life after treatmentmay
open the way for better patient-tailored prevention strategies.
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